Cargando…

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS

Detalles Bibliográficos
Autores principales:	D’souza, Anita, Quock, Tiffany, Conrad, Ansgar, Broder, Michael S., Das, Ashis K., Chang, Eunice, Tarbox, Marian H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429464/ http://dx.doi.org/10.1097/01.HS9.0000975376.22474.27

Ejemplares similares

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database
por: Quock, Tiffany P, et al.
Publicado: (2022)

Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
por: Quock, Tiffany P, et al.
Publicado: (2019)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
por: Reddy, Sheila R., et al.
Publicado: (2020)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

PB1988: AL CARDIAC AMYLOIDOSIS: A CASE SERIES OF 13 PATIENTS AND LITERATURE REVIEW
por: Chadli, S., et al.
Publicado: (2022)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

Association Between Hematologic Response and Change in Health-Related Quality of Life Among Patients with Light-Chain (AL) Amyloidosis
por: Rizio, Avery A, et al.
Publicado: (2023)

PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023)

PB2025: MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS’ SURVEY
por: Santos, S., et al.
Publicado: (2022)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023)

PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS
por: De La Torre De La Paz, M., et al.
Publicado: (2022)

PB2097: CLINICAL IMPLICATION OF CYTOGENETIC ABERRATIONS IN NON-AL AMYLOIDOSIS MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: A MULTI-CENTER CHINESE CASE SERIES
por: Liu, Yang, et al.
Publicado: (2023)

PB2002: OBSERVATIONAL PROSPECTIVE STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN DURATION OF TREATMENT AND RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA OR AL AMYLOIDOSIS: THE DORIANT STUDY (NCT: 04659798)
por: Grande, M., et al.
Publicado: (2022)

PB2709: BURDEN OF SEVERE INFECTIONS IN PRIMARY IMMUNODEFICIENCY DISEASES
por: Aggarwal, Saurabh, et al.
Publicado: (2023)

Increased Clinical and Economic Burden Associated With Peripheral Intravenous Catheter–Related Complications: Analysis of a US Hospital Discharge Database
por: Lim, Sangtaeck, et al.
Publicado: (2019)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

PB2030: CLINICAL, LABORATORY PROFILE, TREATMENT AND OUTCOME OF PRIMARY AMYLOIDOSIS IN THE ERA OF NOVEL AGENTS: AN EXPERIENCE FROM A TERTIARY CARE HOSPITAL IN INDIA
por: Sivaprakasam, Y., et al.
Publicado: (2022)

PB1836: ACUTE MYELOID LEUKEMIA IN OLDER ADULTS IN RESOURCE CONSTRAINT SETTING: SINGLE CENTER DATA FROM SOUTH INDIA
por: Paul, M., et al.
Publicado: (2022)

PB1856: MUTATION STATUS AND ALLELE BURDEN OF FLT3-ITD IN ACUTE MYELOID LEUKEMIA
por: Radzhabova, Asiyat, et al.
Publicado: (2023)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

PB2270: PROGNOSTIC VALUE OF INTERIM POSITRON EMISSION TOMOGRAPHY IN HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA
por: Argumánez, Marta Mora, et al.
Publicado: (2023)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
por: Vera-Llonch, Montserrat, et al.
Publicado: (2021)

2154. How Well Are We Estimating the True Burden of Acute Gastroenteritis? Validation of Acute Gastroenteritis-Related ICD Codes in Pediatric and Adult U.S. Populations
por: Pindyck, Talia, et al.
Publicado: (2018)

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
por: Kastritis, Efstathios, et al.
Publicado: (2023)

PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA
por: Musallam, K. M., et al.
Publicado: (2022)

PB2689: THE PSYCHOLOGICAL EXPERIENCE AND BURDEN OF BLOOD CANCER FOR ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-SYNTHESIS
por: Mehta, Priyanka, et al.
Publicado: (2023)

PB2247: BURDEN OF SYMPTOMS AND SYMPTOM EXPERIENCE OF FILIPINO MYELOPROLIFERATIVE NEOPLASM PATIENTS: A QUALITATIVE PHENOMENOLOGICAL STUDY
por: Mesina, Flordeluna, et al.
Publicado: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
por: MA, Xuefei, et al.
Publicado: (2023)

PB2334: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

PB2472: HOSPITAL BURDEN OF VENO-OCCLUSIVE DISEASE (VOD): COMPARISON OF HOSPITAL STAYS WITH VOD PRINCIPAL VERSUS SECONDARY DIAGNOSIS
por: Aggarwal, Saurabh, et al.
Publicado: (2023)

PB1932: RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Davids, Matthew, et al.
Publicado: (2023)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qisog8q17ch149frer3pgbg2fa